During the evaluation of pre-market approval applications or de novo petitions, the FDA relies upon scientific evidence to assess safety and effectiveness of the device. Experts consider clinical and non-clinical data to gauge the benefits and risks of granting approval.
The new guidance includes the device reviewer’s worksheet, detailing several areas the reviewer considers. These areas include:
• Magnitude of the risks or benefits
• Duration of the risks or benefits
• Probability that patients will experience the risk
• Patient tolerance for risks
• Availability of alternative treatment
• Value the patient places on treatment
The FDA will also increase transparency of the decision-making process with the Summary of Safety and Effectiveness Data for PMAs and additional decision summary review memos for de novo decisions.
More Articles on the FDA:
17 Spine Devices Receive FDA 510(k) Clearance in February
44 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in February
Globus Medical Settles FDA Administrative Complaint
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.